Changing Metabolic Patterns along the Colorectal Adenoma-Carcinoma Sequence.
adenoma
colorectal cancer
lipid metabolism
metabolomics
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
29 Jan 2022
29 Jan 2022
Historique:
received:
23
12
2021
revised:
18
01
2022
accepted:
27
01
2022
entrez:
15
2
2022
pubmed:
16
2
2022
medline:
16
2
2022
Statut:
epublish
Résumé
Colorectal cancer (CRC) is a major public health burden and one of the leading causes of cancer-related deaths worldwide. Screening programs facilitate early diagnosis and can help to reduce poor outcomes. Serum metabolomics can extract vital molecular information that may increase the sensitivity and specificity of colonoscopy in combination with histopathological examination. The present study identifies serum metabolite patterns of treatment-naïve patients, diagnosed with either advanced adenoma (AA) or CRC in colonoscopy screenings, in the framework of the SAKKOPI (Salzburg Colon Cancer Prevention Initiative) program. We used a targeted flow injection analysis and liquid chromatography-tandem mass spectrometry metabolomics approach (FIA- and LC-MS/MS) to characterise the serum metabolomes of an initial screening cohort and two validation cohorts (in total 66 CRC, 76 AA and 93 controls). The lipidome was significantly perturbed, with a proportion of lipid species being downregulated in CRC patients, as compared to AA and controls. The predominant alterations observed were in the levels of lyso-lipids, glycerophosphocholines and acylcarnitines, but additionally, variations in the quantity of hydroxylated sphingolipids could be detected. Changed amino acid metabolism was restricted mainly to metabolites of the arginine/dimethylarginine/NO synthase pathway. The identified metabolic divergences observed in CRC set the foundation for mechanistic studies to characterise biochemical pathways that become deregulated during progression through the adenoma to carcinoma sequence and highlight the key importance of lipid metabolites. Biomarkers related to these pathways could improve the sensitivity and specificity of diagnosis, as well as the monitoring of therapies.
Identifiants
pubmed: 35160173
pii: jcm11030721
doi: 10.3390/jcm11030721
pmc: PMC8836789
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Paracelsus Medical University
ID : E-18/28/148-FEL
Organisme : Financial support from SPAR Austria
Références
Sci Rep. 2020 Feb 6;10(1):1954
pubmed: 32029824
Cancers (Basel). 2020 Jul 13;12(7):
pubmed: 32668616
Cancers (Basel). 2020 Sep 11;12(9):
pubmed: 32932854
Adv Med Sci. 2019 Mar;64(1):104-110
pubmed: 30605863
EBioMedicine. 2021 Dec;74:103734
pubmed: 34875457
Clin Cancer Res. 2012 Oct 15;18(20):5546-53
pubmed: 23071356
Immunity. 2018 Jan 16;48(1):19-33
pubmed: 29343438
Science. 1956 Feb 24;123(3191):309-14
pubmed: 13298683
Gastroenterology. 2013 Jul;145(1):166-175.e8
pubmed: 23541909
Adv Drug Deliv Rev. 2020;159:245-293
pubmed: 32711004
World J Gastroenterol. 2014 Mar 7;20(9):2279-303
pubmed: 24605027
Anal Chim Acta. 2012 Sep 19;743:90-100
pubmed: 22882828
Lung Cancer. 2010 Mar;67(3):361-5
pubmed: 19487045
Expert Rev Anticancer Ther. 2015 Jun;15(6):667-76
pubmed: 25979092
Biochem Biophys Rep. 2015 Aug 29;4:111-125
pubmed: 29124194
Sci Rep. 2019 Dec 16;9(1):19180
pubmed: 31844152
Lipids Health Dis. 2019 Jan 26;18(1):29
pubmed: 30684960
EMBO Mol Med. 2019 Nov 7;11(11):e10698
pubmed: 31602788
Clin Cancer Res. 2018 Jun 1;24(11):2482-2490
pubmed: 29420223
Br J Cancer. 2002 Jun 5;86(11):1691-6
pubmed: 12087451
Mol Cancer. 2008 Sep 18;7:72
pubmed: 18799019
Free Radic Biol Med. 2019 Nov 1;143:354-365
pubmed: 31437479
J Intern Med. 2011 Jul;270(1):41-9
pubmed: 21414047
Immunol Rev. 2014 Nov;262(1):153-66
pubmed: 25319333
Mol Cell Proteomics. 2010 Feb 10;:
pubmed: 20147338
Nat Rev Immunol. 2013 Oct;13(10):709-21
pubmed: 23995626
Front Oncol. 2019 Oct 15;9:1069
pubmed: 31681602
Curr Opin Pharmacol. 2009 Aug;9(4):405-10
pubmed: 19589728
Oncotarget. 2015 Mar 30;6(9):7348-63
pubmed: 25749516
J Natl Cancer Inst. 2012 Mar 7;104(5):343-5
pubmed: 22312133
Curr Pharm Des. 2014;20(38):6048-57
pubmed: 24641220
Cell Biosci. 2019 Dec 2;9:97
pubmed: 31827763
Metabolomics. 2017;13(6):66
pubmed: 28473743
Genes Dev. 2019 Sep 1;33(17-18):1236-1251
pubmed: 31416966
J Transl Med. 2020 Jan 30;18(1):40
pubmed: 32000807
Nat Rev Endocrinol. 2016 Nov;12(11):668-679
pubmed: 27469345
Nat Rev Mol Cell Biol. 2008 Feb;9(2):139-50
pubmed: 18216770
Nat Neurosci. 2020 Feb;23(2):194-208
pubmed: 31959936
Cytokine. 2008 Aug;43(2):149-59
pubmed: 18617418
Clin Cancer Res. 2006 Feb 15;12(4):1144-51
pubmed: 16489067
Cancer Cell Int. 2020 Jun 3;20:207
pubmed: 32514252
BMC Clin Pathol. 2009 Nov 27;9:10
pubmed: 19941666
N Engl J Med. 2016 Mar 17;374(11):1065-75
pubmed: 26981936
Genome Med. 2012 May 14;4(5):42
pubmed: 22583555
Front Oncol. 2020 Jan 09;9:1455
pubmed: 31993367
Prog Lipid Res. 2020 Nov;80:101055
pubmed: 32791170
Cancer Manag Res. 2018 Nov 21;10:6079-6096
pubmed: 30538557
Br J Cancer. 2019 Sep;121(6):483-489
pubmed: 31388184
Transl Res. 2016 Jan;167(1):67-79
pubmed: 26297050
Eur J Vasc Endovasc Surg. 2017 Mar;53(3):439-442
pubmed: 28139409
Curr Opin Gastroenterol. 2013 Mar;29(2):146-52
pubmed: 23283180
Trends Pharmacol Sci. 2015 Jun;36(6):395-405
pubmed: 25930708
Biochem J. 1989 Sep 15;262(3):861-6
pubmed: 2511835
Cancers (Basel). 2021 Jun 02;13(11):
pubmed: 34199435
Cell Death Dis. 2013 Oct 03;4:e830
pubmed: 24091673
BMC Endocr Disord. 2019 Oct 29;19(1):113
pubmed: 31664994
Nat Rev Cancer. 2013 Apr;13(4):227-32
pubmed: 23446547
Clin Transl Oncol. 2021 Feb;23(2):325-334
pubmed: 32607811
Methods. 2005 Jun;36(2):207-24
pubmed: 15894491
Nan Fang Yi Ke Da Xue Xue Bao. 2011 Jan;31(1):1-4
pubmed: 21269946
Cancers (Basel). 2021 Jul 15;13(14):
pubmed: 34298755
Commun Biol. 2020 May 22;3(1):252
pubmed: 32444775
Cancer Immunol Immunother. 2014 Jul;63(7):721-35
pubmed: 24711084
J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Nov 15;1068-1069:41-48
pubmed: 29028617
Lipids. 2015 Apr;50(4):349-58
pubmed: 25595595
Nat Rev Dis Primers. 2015 Nov 05;1:15065
pubmed: 27189416
Theranostics. 2019 Sep 25;9(24):7251-7267
pubmed: 31695766
Dis Markers. 2019 Apr 7;2019:3491852
pubmed: 31089393
Anal Bioanal Chem. 2012 Sep;404(4):1239-45
pubmed: 22648167
Nat Rev Immunol. 2021 Oct;21(10):653-667
pubmed: 33911231
Cancer Res. 1986 Dec;46(12 Pt 1):6513-9
pubmed: 2946404
PLoS One. 2017 Sep 28;12(9):e0185294
pubmed: 28957370
Proc Natl Acad Sci U S A. 2017 Sep 12;114(37):E7697-E7706
pubmed: 28847964
PLoS One. 2015 Apr 16;10(4):e0122046
pubmed: 25881064
PLoS One. 2018 May 22;13(5):e0197148
pubmed: 29787597
Nat Rev Cancer. 2011 Nov 17;11(12):835-48
pubmed: 22089420
Br J Nutr. 2004 May;91(5):715-23
pubmed: 15137923
Clin Cancer Res. 2012 Oct 15;18(20):5537-45
pubmed: 23071355
Cell. 2010 Mar 19;140(6):883-99
pubmed: 20303878
J Clin Oncol. 2007 Jul 1;25(19):2696-701
pubmed: 17602074